Prescient Therapeutics Past Earnings Performance
Past criteria checks 0/6
Prescient Therapeutics's earnings have been declining at an average annual rate of -17.6%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 17.7% per year.
Key information
-17.6%
Earnings growth rate
10.8%
EPS growth rate
Biotechs Industry Growth | 9.6% |
Revenue growth rate | 17.7% |
Return on equity | -34.3% |
Net Margin | -248.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate
Nov 14Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth
Aug 01Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why
Nov 22Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Oct 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Jun 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Feb 27We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now
Nov 05We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth
Aug 26Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans
May 08Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?
Jan 11Revenue & Expenses BreakdownBeta
How Prescient Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 3 | -8 | 4 | 8 |
30 Sep 23 | 3 | -7 | 4 | 7 |
30 Jun 23 | 2 | -7 | 4 | 6 |
31 Mar 23 | 2 | -6 | 4 | 5 |
31 Dec 22 | 2 | -5 | 4 | 4 |
30 Sep 22 | 2 | -5 | 4 | 4 |
30 Jun 22 | 2 | -5 | 4 | 3 |
31 Mar 22 | 2 | -5 | 4 | 3 |
31 Dec 21 | 1 | -5 | 4 | 3 |
30 Sep 21 | 1 | -5 | 3 | 3 |
30 Jun 21 | 1 | -4 | 3 | 2 |
31 Mar 21 | 1 | -4 | 2 | 3 |
31 Dec 20 | 1 | -3 | 2 | 3 |
30 Sep 20 | 1 | -3 | 2 | 3 |
30 Jun 20 | 1 | -3 | 2 | 3 |
31 Mar 20 | 1 | -4 | 2 | 3 |
31 Dec 19 | 2 | -4 | 2 | 3 |
30 Sep 19 | 2 | -4 | 2 | 4 |
30 Jun 19 | 2 | -4 | 2 | 4 |
31 Mar 19 | 1 | -3 | 2 | 3 |
31 Dec 18 | 1 | -3 | 2 | 3 |
30 Sep 18 | 1 | -3 | 2 | 2 |
30 Jun 18 | 1 | -3 | 2 | 2 |
31 Mar 18 | 1 | -3 | 1 | 2 |
31 Dec 17 | 1 | -3 | 1 | 2 |
30 Sep 17 | 1 | -3 | 1 | 2 |
30 Jun 17 | 1 | -3 | 1 | 2 |
31 Mar 17 | 1 | -2 | 2 | 2 |
31 Dec 16 | 1 | -2 | 2 | 1 |
30 Sep 16 | 1 | -2 | 2 | 1 |
30 Jun 16 | 1 | -2 | 2 | 1 |
31 Mar 16 | 1 | -2 | 2 | 1 |
31 Dec 15 | 1 | -2 | 2 | 1 |
30 Sep 15 | 1 | -2 | 1 | 1 |
30 Jun 15 | 0 | -2 | 1 | 1 |
31 Mar 15 | 0 | -2 | 1 | 1 |
31 Dec 14 | 0 | -2 | 1 | 0 |
30 Sep 14 | 0 | -2 | 1 | 0 |
30 Jun 14 | 0 | -2 | 1 | 0 |
31 Mar 14 | 0 | -1 | 1 | 0 |
31 Dec 13 | 0 | -1 | 1 | 0 |
30 Sep 13 | 0 | 0 | 1 | 0 |
Quality Earnings: PTX is currently unprofitable.
Growing Profit Margin: PTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PTX is unprofitable, and losses have increased over the past 5 years at a rate of 17.6% per year.
Accelerating Growth: Unable to compare PTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: PTX has a negative Return on Equity (-34.25%), as it is currently unprofitable.